端粒维护特征预测结肠直肠癌的预后和治疗反应
Yanpin Ma1, Xiangjie Fang2, Penghui Li1
1Department of Oncology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000, China.
Current topics in medicinal chemistry
|July 17, 2025
概括
这项研究确定了与端粒维护相关的基因 (TMG) 作为结直肠癌 (CRC) 预后和免疫治疗反应的关键预测因素. 使用CDC25C和USP39的新型风险评分模型有助于个性化CRC治疗策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 端粒长度与结直肠癌 (CRC) 风险和存活率有关.
- 端粒维护相关基因 (TMG) 在CRC预后和免疫治疗反应中的作用需要进一步调查.
研究的目的:
- 确定TMG用于预测CRC患者的免疫治疗反应和预后.
- 开发CRC预后的风险评分模型,并评估其与药物敏感性的相关性.
主要方法:
- 利用TCGA和GEO数据库进行CRC基因表达和临床数据.
- 使用权重基因共同表达分析 (WGCNA) 来识别TMG相关的基因模块.
- 使用对关键预后基因的考克斯回归分析构建了一个风险得分模型 (CDC25C,USP39).
主要成果:
- 较高的TMG得分与较差的免疫透和CRC中的 stromal得分相关.
- 开发的风险评分模型证明了独立队列的良好生存预测.
- 高风险患者表现出免疫细胞透的改变和对大多数药物的敏感性降低.
结论:
- 基于CDC25C和USP39的TMG相关签名有效预测CRC预后和免疫治疗反应.
- 建立的风险评分模型为CRC的预后预测提供了一个可靠的工具.
- TMG为CRC开发个性化治疗策略提供了一个新的分子基础.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Replicative Cell Senescence
3.7K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.7K
Telomeres and Telomerase
24.1K
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
24.1K
Replication in Eukaryotes
14.7K
In eukaryotic cells, DNA replication is highly conserved and tightly regulated. Multiple linear chromosomes must be duplicated with high fidelity before cell division, so there are many proteins that fulfill specialized roles in the replication process. Replication occurs in three phases: initiation, elongation, and termination, and ends with two complete sets of chromosomes in the nucleus.
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
14.7K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


